A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

NCT01204996 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
DRUG: CNTO888 + gemcitabine
DRUG: CNTO888 + Paclitaxel and carboplatin
DRUG: CNTO888 + docetaxel

Sponsor

Centocor, Inc.